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A B S T R A C T
Background
Cystic ﬁbrosis is an inherited recessive disorder of chloride transport that is characterised by recurrent and persistent pulmonary
infections from resistant organisms that result in lung function deterioration and early mortality in sufferers.
Meticillin-resistant Staphylococcus aureus (MRSA) has emerged as, not only an important infection in long-term hospitalised patients,
but also as a potentially harmful pathogen in cystic ﬁbrosis, and has been increasing steadily in prevalence internationally. Chronic
pulmonary infection with MRSA is thought to confer cystic ﬁbrosis patients with a worse overall clinical outcome and, in particular,
result in an increased rate of decline in lung function. Clear guidance for the eradication of MRSA in cystic ﬁbrosis, supported by
robust evidence from good quality trials, is urgently needed.
Objectives
To evaluate the effectiveness of treatment regimens designed to eradicate MRSA and to determine whether the eradication of MRSA
confers better clinical and microbiological outcomes for people with cystic ﬁbrosis.
Search methods
Randomised and quasi-randomised controlled trials were identiﬁed by searching the Cochrane Cystic Fibrosis and Genetic Disorders
Group’s Cystic Fibrosis Trials Register, PUBMED, MEDLINE, Embase, handsearching article reference lists and through contact with
local and international experts in the ﬁeld.
Date of the last search of the Group’s Cystic Fibrosis Trials Register: 04 September 2014.
Selection criteria
Randomised or quasi-randomised controlled trials comparing any combinations of topical, inhaled, oral or intravenous antimicrobials
with the primary aim of eradicating MRSA compared with placebo, standard treatment or no treatment.
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Data collection and analysis
The authors independently assessed all search results for eligibility. No eligible trials were identiﬁed for inclusion.
Main results
No current published eligible trials were identiﬁed, although three ongoing clinical trials are likely to be eligible for inclusion in future
updates of this review.
Authors’ conclusions
We did not identify any randomised trials which would allow us to make any evidence-based recommendations. Although the results
of several non-randomised studies would suggest that, once isolated, the eradication of MRSA is possible; whether this has a signiﬁcant
impact on clinical outcome is still unclear. Further research is required to guide clinical decision making in the management of MRSA
infection in cystic ﬁbrosis.
P L A I N L A N G U A G E S U M M A R Y
Interventions to clear meticillin-resistant Staphylococcus aureus (MRSA) from the lungs of people with cystic fibrosis
Review question
We looked for evidence to determine the effect of different ways of clearing meticillin-resistant Staphylococcus aureus (MRSA) from the
lungs of people with cystic ﬁbrosis.
Background
Meticillin-resistant Staphylococcus aureus (MRSA), is the name given to a particular bacteria which is resistant to some types of antibiotics.
This is particularly worrying for people with cystic ﬁbrosis, which is an inherited condition that causes thick mucus to build up in the
lungs. It is very difﬁcult for people with cystic ﬁbrosis to cough up this thick mucus, making it an ideal breeding ground for bacteria,
including MRSA, and making these people more prone to chest infections. It is thought that MRSA can cause more damage than other
bacteria which are not resistant to antibiotics. We wanted to identify research evidence to support the best way for treating MRSA
infections and also to see if this would improve the lives of people with cystic ﬁbrosis.
Search date
The evidence is current to: 04 September 2014.
Key results
Unfortunately, we could not ﬁnd any trials which compared treating MRSA to not treating MRSA, or which compared one form of
treatment to another. We are unable, therefore, to make any recommendations for its management at this point in time.
B A C K G R O U N D
Description of the condition
Cystic ﬁbrosis (CF) is themost common autosomal inherited con-
dition in the Caucasian population, with a gene carrier rate of 1
in 25 and affecting around 1 in 2500 newborns in the UK (CF
Trust UK 2011). It is a multisystem disorder resulting from a dis-
ruption in chloride transport at the cellular level leading to abnor-
mal, dehydrated secretions within the lungs. This results in im-
paired mucociliary clearance leading to recurrent pulmonary in-
fections, bronchiectasis and progressively deteriorating lung func-
tion, which is the main cause of the morbidity and mortality seen
in CF.
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Organism
The abbreviation MRSA stands for meticillin-resistant Staphylo-
coccus aureus (S. aureus). Meticillin is an antibiotic that is no longer
in clinical use, but MRSA is resistant to antibiotics within the
same class. This includes ﬂucloxacillin, which is prescribed both
for prophylaxis and treatment of infection with S. aureus in peo-
ple with CF in the UK. Furthermore, MRSA is also resistant to
other antibiotics in the beta lactam family such as cephalosporins
(e.g. ceftazidime) and carbapenems (e.g. meropenem). Resistance
is not due to production of beta lactamase enzymes, but rather to
the production of altered penicillin-binding proteins coded on the
mecA gene.
Most MRSA infections in both the non-CF and CF populations
have been so-called ’healthcare associated’ (HA-MRSA), which oc-
cur in patients who have been hospitalised, had surgery, are on dial-
ysis, or who have had invasive procedures.However, in recent years
outbreaks of ’community-acquired’ MRSA (CA-MRSA) have oc-
curred in otherwise healthy people with no link to a healthcare
facility (Chambers 2009). This distinction by patient location at
time of infection is becoming increasingly difﬁcult, given out-
breaks of strains of CA-MRSA in hospitals, and the spread of HA-
MRSA strains in the community through people with chronic ill-
nesses.
It is possible to further classify MRSA according to the staphy-
lococcal chromosome cassette mec (SCCmec) type, on which the
mecA gene is located. Several distinct types have been described to
date, of which HA-MRSA is associated with types I to III. These
SCCmec types also encode for resistance to other classes of an-
tibiotics, thus making HA-MRSA overall more resistant. So-called
CA-MRSA carries SCCmec types IV and V. Although CA-MRSA
usually has the smaller type IV SCCmec type, which lacks some of
the antibiotic resistance determinants possessed by types I to III,
it is also more frequently associated with the production of the
virulence factor Panton-Valentine leucocidin (PVL), a cytotoxin
which causes leucocyte destruction and tissue necrosis.
Although patients withMRSA have been found to require a higher
intensity of treatment when compared with their meticillin-sensi-
tive S. aureus (MSSA) counterparts, this is further complicated by
differences observed between different MRSA types (Muhlebach
2011). For instance, the emergence of PVL-positive CA-MRSA
within the CF population has been described and one report sug-
gests this to be associated with a more severe clinical course acutely
compared with PVL-negative CA- or HA-MRSA strains (Elizur
2007).
Prevalence
The prevalence of MRSA varies throughout Europe. As reported
by the European Centre for Disease Prevention and Control, in
the UK 25% to 50% of isolates of S. aureus are found to be MRSA
compared to less than 1% in Norway (ECDC 2009). In the USA,
the proportion of healthcare-associated S. aureus infections found
in intensive care units that are attributable to MRSA has increased
from 2% in 1974 to 64% in 2004 (Klevens 2006).
Amongst peoplewithCF, the prevalence of chronicMSSA (deﬁned
as three or more recorded isolates) in the UK has increased from
7.3% in 2001 to 15.2% in 2009, with the prevalence of MRSA
(deﬁned as any single isolate) at 2.5% (CF Trust 2009).
TheUSACF registry data from2009 recorded any isolate ofMSSA
at 51.3% and any isolate of MRSA at 23.7%, with 65.8% of their
CF population having positive cultures for eitherMSSA orMRSA
(CF Foundation 2009). The most recent 2010 data reports the
prevalence ofMSSA at 67%andMRSA at 25.7% (CF Foundation
2010).
In Australia, the 2009 CF registry reports a MSSA prevalence of
43% and MRSA prevalence of 4.2% as a proportion of tested
patients via any culture method and including any single positive
isolate (Cystic Fibrosis Australia 2011).
Condition
As described above, one of the early key pathogens in CF-lung
disease is MSSA, but increasingly MRSA has been cultured from
the lower respiratory tracts of people with CF. The role of MRSA
in CF-lung disease remains debated.
A large observational study looking at 1834 patients who had pos-
itive respiratory cultures for S. aureus (MRSA or MSSA) found
that presence of MRSA in respiratory cultures was associated with
poorer lung function, more courses of antibiotics and longer hos-
pital stays when compared with those colonised with MSSA (Ren
2007). However, the authors were unable to conclude whether
their ﬁndings were due to cause or effect.
Two studies were published in 2008 addressing this point, but
came to differing conclusions (Dasenbrook 2008; Sawicki 2008).
Dasenbrook suggested that chronic, though not intermittent, de-
tection of MRSA in respiratory tract cultures of people with CF
(as deﬁned by reports from the CF Foundation Registry) is associ-
ated with poorer survival and reduced lung function (Dasenbrook
2008; Dasenbrook 2010). By contrast, Sawicki concluded that al-
though MRSA was a marker for more aggressive therapy and may
reﬂect increased disease severity, MRSA detection was not associ-
ated with a signiﬁcant decline in lung function (Sawicki 2008).
Although both were longitudinal studies, Sawicki analysed data
from an observational study of people with CF in North America
(Epidemiologic Study of Cystic Fibrosis (ESCF) (Morgan 1999))
using multivariate linear regression analysis to study the impact of
MRSA on lung function (forced expiratory volume in one second
(FEV1) per cent (%) predicted); whilstDasenbrookuseddata from
the CF Foundation Registry. One of the fundamental differences
between the two studies is the inclusion criteria. Sawicki included
patients for analysis who had only one positive culture for MRSA
(23% of cohort) whilst Dasenbrook studied patients with three
or more positive cultures, those with one or two MRSA cultures
were excluded.
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Despite these differences, both studies reported an increased rate
of decline in FEV1 % predicted of around 0.5% in their ’before’
and ’after’ MRSA groups. It is possible that this did not reach
statistical signiﬁcance in the Sawicki paper secondary to the smaller
cohort size (593 versus 1732). An increased rate of decline of
0.8% has more recently been reported by a group in Belgium
who conducted a retrospective case-control study based at a single
centre (Vanderhelst 2012).
In terms of survival, Dasenbrook found that detection of MRSA
from the respiratory tract of CF patients was associated with a
risk of death 1.27 (95% conﬁdence interval (CI) 1.11 to 1.45)
times that of individuals in whomMRSA had never been detected
(Dasenbrook 2010). Perhaps ofmore clinical importance however,
is that they also found that patients who clear MRSA within one
year have the same risk of death as those who never have a positive
culture for MRSA. This emphasizes the importance and need for
clear guidance on how we manage MRSA infection in CF.
Description of the intervention
Currently in the UK, children are prescribed prophylactic anti-
staphylococcal antibiotics (ﬂucloxacillin) from diagnosis until
three years of age with resultant fewer isolates of S. aureus, though
the clinical signiﬁcance of this ﬁnding remains uncertain (Smyth
2003). However, the US Cystic Fibrosis Foundation recommend
against the use of prophylaxis in anticipation that this may lead to
an increase in colonisation of Pseudomonas aeruginosa (P. aerugi-
nosa) (Flume 2007).
Some authors suggest a pragmatic approach would be to treat
every isolate of MRSA or MSSA with eradication therapy (Solis
2003).However, this approach, with its frequent use of antibiotics,
would run the risk of increasing the incidence of multi-resistant
organisms that are less susceptible to treatment, whilst potentially
adding to the already substantial treatment burden that people
with CF face.
Certainly in the case of HA-MRSA infections, there has been
encouraging progress since the introduction of stringent MRSA
screening and eradication measures in hospitals. The 2010 report
by the Centers for Disease Control and Prevention showed a 28%
decline in invasive MRSA infections originating in hospitals be-
tween 2005 and 2008 in the USA (Kallen 2010). Whilst in the
UK, the Department of Health target to reduce MRSA blood-
stream infections by 50% from its peak levels in 2003 to 2004 was
achieved by 2008 (Liebowitz 2009; Pearson 2009).
Why it is important to do this review
Despite the increasingprevalence ofMRSA, its clinical signiﬁcance
remains unclear and there remains no international consensus for
its management.With the increasing prevalence of resistant strains
of S. aureus, it becomes more important for any therapeutic ap-
proaches with antibiotics to be justiﬁed with the most up-to-date
evidence, especially in patients with chronic medical conditions.
A previous Cochrane review could not ﬁnd enough evidence to
support the use of any single or combination of therapies for erad-
icating nasal or extra-nasal colonisation of MRSA over another
(Loeb 2003). Most studies addressing MRSA colonisation have
been done in either healthy carriers or people in chronic care fa-
cilities, but not in those with chronic lung disease as seen in CF.
Such reports include a variety of interventions, often focusing on
nasal and skin colonisation, thus such ﬁndings may not be directly
applicable to CF. However, a retrospective review of MRSA eradi-
cation practice in a single large UK adult CF centre showed some
promise (Doe 2010). They used varying eradication regimes based
on sensitivity patterns and individual tolerability, including strin-
gent patient segregation and topical decolonisation, to attempt
MRSA eradication from sputum and skin in CF patients. Over a
10-year period they reported an eradication rate of 81% (deﬁned
as three consecutive negative sputum and peripheral cultures over
six months), though the clinical impact of what successful MRSA
eradication meant for patients was not reported.
The 2008UKCFTrust consensus statement document stated that
in the absence of prospective randomised clinical trials looking at
the effect on lung function which chronic carriage with MRSA
confers, MRSA infection will lead to a reduction in antibiotic
treatment options and a likelihood of a deterioration in lung func-
tion. It is therefore their recommendation that the eradication of
MRSA should be attempted for positive cases (CF Trust 2008).
The rationale for this review is to determine the success of MRSA
eradication for people with CF, and to question whether eradica-
tion confers improved clinical outcomes. This version of the re-
view is an update of the original review (Lo 2013).
O B J E C T I V E S
To evaluate the effectiveness of treatment regimens designed to
eradicate MRSA and to determine whether the eradication of
MRSA confers better clinical and microbiological outcomes for
patients with CF.
To ascertain whether attempts at eradicating MRSA can lead to
increased acquisition of other resistant organisms (including P.
aeruginosa) or increased adverse effects from drugs, or both.
M E T H O D S
Criteria for considering studies for this review
Types of studies
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Randomised or quasi-randomised controlled trials.
Types of participants
Children and adults diagnosed with CF clinically and by sweat or
genetic testing with a conﬁrmed positive microbiological isolate of
MRSA on clinically relevantCF respiratory cultures (bronchoalve-
olar lavage (BAL), cough or oropharyngeal swab, spontaneous or
induced sputum culture) specimen prior to enrolment into the
trial.
We included all disease severities.We did not include patients with
nasal carriage of MRSA alone in this review.
Types of interventions
Any combinations of topical, inhaled, oral or intravenous an-
timicrobials with the primary aim of eradicating MRSA once de-
tected on clinically relevantCF respiratory cultures comparedwith
placebo, standard treatment or no treatment.
Types of outcome measures
Primary outcomes
1. Eradication of MRSA (as deﬁned by negative respiratory
culture after completion of the eradication protocol)
2. Time until next positive MRSA isolate from clinically
relevant respiratory culture
Secondary outcomes
1. Lung function
i) forced expiratory volume at one second (FEV1) %
predicted
ii) forced vital capacity (FVC) % predicted
iii) other validated measures of lung function
2. Overall antibiotic use
3. Mortality
4. Quality of life measured using a validated tool
i) CF Questionnaire-Revised version (CFQ-R)
(Quittner 2009)
ii) CF Quality of Life Questionnaire (CFQoL) (Gee
2000)
5. Isolation of MRSA or other organisms with new antibiotic
resistant phenotypes
i) P. aeruginosa
ii) other previously uncultured organism
iii) small colony variants
6. Growth and nutritional status
i) weight (kg)
ii) height (cm)
iii) body mass index (BMI) (kg/m2)
iv) lean body mass (%)
v) fat body mass (%)
7. Adverse effects to treatment
i) mild (not requiring treatment)
ii) moderate (requiring treatment or admission or
cessation of treatment, or a combination of any of these)
iii) severe (life-threatening)
8. Elimination of carrier status (nasal or skin)
9. Frequency of exacerbations
10. Cost of care
Search methods for identification of studies
Electronic searches
We identiﬁed relevant studies from the Group’s Cystic Fibrosis
Trials Register using the terms: (Staphylococcus aureus OR mixed
infections) AND (eradication OR unknown).
The Cystic Fibrosis Trials Register is compiled from electronic
searches of the Cochrane Central Register of Controlled Trials
(CENTRAL) (updated each new issue of The Cochrane Library),
weekly searches ofMEDLINE, a search of Embase to 1995 and the
prospective handsearching of two journals - Pediatric Pulmonology
and the Journal of Cystic Fibrosis. Unpublished work is identiﬁed
by searching the abstract books of three major cystic ﬁbrosis con-
ferences: the International Cystic Fibrosis Conference; the Euro-
pean Cystic Fibrosis Conference and the North American Cystic
Fibrosis Conference. For full details of all searching activities for
the register, please see the relevant sections of the Cochrane Cystic
Fibrosis and Genetic Disorders Group Module. Date of the latest
search of the Group’s CF Register: 04 September 2014.
We
searched for relevant trials via the websites www.clinicaltrials.gov
and www.isrctn.org using the search terms (Cystic Fibrosis AND
MRSA). Date of latest search: 10 December 2014.
We also independently searched PUBMED, MEDLINE (1950 to
December 2014) and Embase (1980 to December 2014) via the
OpenAthens access management system using the search strategy
detailed below - see Appendix 1. Date of latest search: 10 Decem-
ber 2014.
Searching other resources
We will also contact primary authors and research institutions of
any future identiﬁed trials for unpublished data.
Data collection and analysis
We were unable to identify any eligible and completed trials for
inclusion in this review. We have detailed our methodology for
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selection of trials and also the planned methodology for data anal-
ysis should eligible studies become available in future searches.
Selection of studies
Two authors (DL, MH) independently screened trials for inclu-
sion in this review using methods in accordance with methods de-
scribed byHiggins in theCochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011a). Both authors independently ex-
amined the title and abstracts to exclude duplicate publications,
case reports, review articles and unrelated articles. Of the remain-
ing studies, DL and MH independently examined the full text
publications to determine if they met our eligibility criteria. The
authors planned to resolve any disagreements on the eligibility of
studies by consulting with the third and fourth authors (MM, AS)
for advice and reaching a consensus through discussion between
all authors.
Data extraction and management
Should any eligible studies become available in future searches,
two authors (DL, MH) will extract data using standardised data
acquisition forms upon which all authors have agreed. They will
resolve disagreements through discussion between all four authors.
Where information is incomplete or unclear, the authors will at-
tempt to contact the lead author of the paper where possible.
The authors plan to group outcome data into those measured at
up to 14 days, up to 1month, up to 3months, up to 6months and
up to 12 months after MRSA therapy. All authors will consider
data for inclusion which was recorded at other time intervals and
highlight this in the report.
Assessment of risk of bias in included studies
The authors will assess the risk of bias using methods described
in theCochrane Handbook for Systematic Reviews for Interventions
(Higgins 2011b). In particular each author will examine themeth-
ods to determine the adequacy of randomisation and blinding,
and also whether any participants lost to follow-up are accounted
for and justiﬁed. They will also seek to identify any selective re-
porting by comparing the full report to the protocol.
In addition, each author will independently use the ’risk of bias’
assessment tool available in section 8.5 of the Cochrane Handbook
for Systematic Reviews for Interventions in order to judge each of
the described seven domains as having low, high or unclear risk of
bias (Higgins 2011b).
Measures of treatment effect
For dichotomous data (e.g. eradication achieved or not), the au-
thors plan to analyse the data on an intention-to-treat basis, ir-
respective of compliance or dropout secondary to adverse effects.
They will sort the data based on each possible outcome event for
each treatment arm and calculate the odds ratio (OR) and its 95%
CI.
For continuous data, the authors plan to calculate the mean dif-
ference (MD) of effect of each variable along with its 95% CI.
Where two or more studies measure the same outcome but using
different scales, they aim to calculate the standardised mean dif-
ference (SMD) with its 95% CI.
The authors plan to extract ordinal and count data in all forms in
which they are reported and plan to analyse these as per continuous
data for common outcomes; for rare outcomes they will follow
the advice in section 9.2.5 of theCochrane Handbook for Systematic
Reviews of Interventions (Deeks 2011).
For time-to-event data (e.g. time to next exacerbation), they plan
to calculate the hazard ratio (HR) at individual time points (at 14
days, then 1, 3, 6 and 12 months) along with its 95% CI.
Unit of analysis issues
Cross-over studies are not eligible for inclusion within this review
since the authors are reviewing how efﬁcacious the initial attempt
at eradication of MRSA is when compared with placebo, usual
treatment or no treatment. Subsequently, they aim to evaluate time
until next positive MRSA culture and number of further courses
of antibiotics required following each arm of therapy.
The authors do not plan to include cluster-randomised controlled
trials. When randomisation is performed according to patient
groups, certain strains of MRSA (which may differ between com-
munities) could potentially be over-represented in either the treat-
ment or placebo arm and hence bias the results.
Dealing with missing data
In cases where data are missing which relate to either the review’s
primary or secondary outcomes, the authors will attempt to con-
tact the primary investigator for clariﬁcation. If they are not able
to contact the primary investigator, they will attempt to contact
the co-investigators and sponsors.
Assessment of heterogeneity
In order to assess heterogeneity between studies the authorswill use
the I2 statistic and the chi-squared test. As stated in theCochrane
Handbook for Systematic Reviews of Interventions, the importance of
the observed value of I2 depends on (i) themagnitude anddirection
of effects and (ii) the strength of evidence for heterogeneity (e.g. P
value for chi-squared) (Higgins 2011a). The authors will consider
values of 0% to 40% to represent little to no heterogeneity, 30%
to 60% moderate, 60% to 90% substantial and values of more
than 90% as demonstrating considerable heterogeneity.
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Assessment of reporting biases
The authors plan to assess for selective reporting of results by com-
paring (where available) the outcomes listed in the original pro-
tocol to those reported in the ﬁnal paper. They will also search
clinical trials registers for any completed studies relevant to our
review that may not have been published. They plan to attempt to
contact the primary investigators of identiﬁed trials to determine
whether they are aware of any relevant unpublished data. Thismay
help to identify some small studies which may not have reported
statistically signiﬁcant outcomes. The authors aim to identify pub-
lication bias with the construction of funnel plots, although they
are wary of other potential causes for asymmetry.
Data synthesis
The authors aim to analyse extracted data using a ﬁxed-effectmeta-
analysis unless the heterogeneity between studies is found to be
substantial (more than 60%), at which point they will perform a
random-effects meta-analysis.
Subgroup analysis and investigation of heterogeneity
If the authors identify a sufﬁcient number of studies (more than
10) and also ﬁnd substantial heterogeneity between studies, they
will investigate this with subgroup analysis of the following:
1. eradication therapy commenced at initial acquisition versus
following chronic colonisation (three or more positive cultures
over a 12-month period);
2. duration of eradication therapy (up to and including 6
weeks, 7 to 12 weeks, over 12 weeks);
3. intravenous versus aerosolised versus oral administration of
antibiotics;
4. efﬁcacy of regimens which include methods for skin or
nasal eradication, or both, versus those that do not.
Sensitivity analysis
Where outcome measures have been chosen based upon arbitrary
values, the authors plan to re-evaluate the effect that alternative
endpoints have on their ﬁndings. For instance, some studies may
use a cut-off of longer than 14 days to represent successful eradi-
cation of MRSA, where the available data allows, the authors will
repeat the analysis of treatment effect using different cut-offs (1,
3, 6 or 12 months).
With regards to smaller studies (20 participants in each group
or less) that the authors may include in the initial meta-analyses,
they aim to repeat the analyses without these smaller studies to
determine their effect.
R E S U L T S
Description of studies
Results of the search
A total of 54 references to 41 studies were identiﬁed from the
CFGD Group’s CF Trials Register. Seven additional studies were
identiﬁed from a separate PUBMED, EMBASE and MEDLINE
search. Three ongoing studies were identiﬁed from the ongoing
trials registers www.clinicaltrials.gov and www.isrctn.org. These
ongoing trials may be eligible for inclusion into future versions
of this review: ’Early meticillin-resistant Staphylococcus aureus
(MRSA) therapy in cystic ﬁbrosis (CF)’ (NCT01349192), ’Persis-
tent meticillin-resistant Staphylococcus aureus eradication protocol’
(NCT01594827) and ’Efﬁcacy and safety study of AeroVanc for
the treatment of persistent MRSA lung infection in cystic ﬁbrosis
patients’ (NCT01746095). Details of these studies can be found
in the tables (Characteristics of ongoing studies). Please also see
the PRISMA diagram (Figure 1).
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Figure 1. Study flow diagram.
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Included studies
The authors did not identify any studies which were eligible for
inclusion in the current version of this review.
Excluded studies
Of the 41 excluded studies from the results of the search of the
Cystic Fibrosis and Genetic Disorders Group’s CF Trials Register,
12 were pharmacokinetic studies, one was a tolerability study and
the remaining 28 were excluded because the participants or inter-
ventions were not relevant to our review (See: Characteristics of
excluded studies). None of the 41 studies had the primary intent
of MRSA eradication in people with CF.
Of the seven additional studies identiﬁed, all had relevant partici-
pants, interventions and outcomes but these were not included as
they were not randomised or controlled studies. All had the pri-
mary aim of MRSA or S.aureus (one study) eradication in people
with CF. Two were case reports, one of a 10-year old boy (Maiz
1998) and one of a 28-year old man (Serisier 2004). Four were
observational studies (Garske 2004; Macfarlane 2007; Dalbøge
2013; Vanderhelst 2013) and one was a retrospective study (Solis
2003).
Risk of bias in included studies
No studies were identiﬁed which were eligible for inclusion in this
review.
Effects of interventions
No studies were identiﬁed which were eligible for inclusion in this
review.
D I S C U S S I O N
Summary of main results
Although MRSA is an important emerging pathogen in CF respi-
ratory illness, there is no widely accepted consensus for its optimal
management. The broad search terms used in this review identiﬁed
a large number of studies listed on the Cochrane CFGD Group’s
CF Trials Register, unfortunately none of them were relevant or
eligible for inclusion. Most of the studies identiﬁed dealt primarily
with P. aeruginosa treatment in CF and not with MRSA.
Overall completeness and applicability of
evidence
There are currently three ongoing prospective studies awaiting
completion, which will potentially be eligible for inclusion in fu-
ture versions of this review. One study examines the eradication
of early MRSA acquisition, whilst the other two examines man-
agement of persistent infection (see Characteristics of ongoing
studies). One of these is currently recruiting participants and is
estimated to complete inMarch 2015 (NCT01594827) whilst the
other two studies have completed patient enrolment and results
are awaited (NCT01349192 and NCT01746095). All three stud-
ies will compare an active treatment group to an observational/
placebo group.
Quality of the evidence
The available evidence for this review is poor, with no published
randomised controlled trials and only a few observational or ret-
rospective studies at present.
Potential biases in the review process
One of the co-authors of this review (MM) is the lead investigator
of one of the ongoing clinical trials (NCT01349192).
Agreements and disagreements with other
studies or reviews
Various strategies have been proposed for the eradication ofMRSA
when isolated fromCF respiratory samples. It has become apparent
from this review that these are based on anecdotal evidence or,
at best, a small number of observational studies involving small
numbers of participants.
The authors identiﬁed seven non-randomised and non-controlled
studies; three in paediatric participants (age range 1 to 16 years),
two in adults (age range 22 to 36 years) and two inmixedpaediatric
and adult groups. With the exception of Maiz 1998 (a case report
on one 10-year old boy), and Dalbøge 2013 (a cohort study which
reports on efﬁcacy of S.aureus eradication, where only 0.3% of
subjects were MRSA positive), the remaining ﬁve studies reported
successful eradication of MRSA in, at least a proportion of, their
participants (Garske 2004; Macfarlane 2007; Serisier 2004; Solis
2003; Vanderhelst 2013).
Whilst in the Maiz 1998 case report MRSA was not eradicated
after the 17-month treatment with daily continuous inhaled van-
comycin, the authors did report improvements in lung function
and symptom score in the child. The Vanderhelst 2013 study
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reported a non-statistically signiﬁcant trend in improvement of
FEV1% in the 11 patients they studied, after successful eradication
of MRSA. The largest cohort study (Dalbøge 2013) successfully
eradicated Staphylococcus aureus from the sputum samples of the
65 patients they treated, and reported a statistically signiﬁcant me-
dian (range) improvement in FEV1% predicted of 3.3% (−25%
to 36%, p<0.0001). However, they did not differentiate between
those patients who grew MSSA or those who grew MRSA from
their sputum.
This is contradictory to two other studies, which reported no
signiﬁcant differences in lung function between participants who
were successfully eradicated when compared to those who were
not (Garske 2004; Solis 2003); however, this may be because the
numberswere too small to detect a difference. The ﬁnal two studies
reported successful eradication of MRSA, Macfarlane 2007 (in
94% of patients) and Serisier 2004 (in one 28-year old), but did
not report on lung function or patient clinical status during or
following eradication.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is currently no published evidence from randomised con-
trolled trials to support any one eradication regimen over another.
While there are reports of successful eradication in those with CF,
there is considerable uncertainty whether this is associated with
patient beneﬁt.
Implications for research
This reviewhas highlighted the lack of evidence behind the present
management of MRSA respiratory infections in CF and empha-
sizes the need for well-designed, adequately-powered trials with
long-term follow-up in order to address this.
These will need to address the questions.
1. Does eradication of MRSA confer a favourable prognosis
(see Types of outcome measures) for people with CF?
2. What is the optimal duration of treatment?
3. What is the most effective method of providing treatment
(oral or intravenous or inhaled)?
4. Are there any pitfalls to treating MRSA aggressively (i.e.
selection for other resistant pathogens, reduced patient
tolerability)?
The published reports of the two ongoing studies identiﬁed are
keenly awaited and the authors look forward to assessing the pub-
lished data of these for inclusion into a future update of this review.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Adeboyeku 2001 Not a relevant intervention - tolerability study of differing dosages of nebulised colistin
Amelina 2000 Not a relevant intervention or participants - difference in quality of life between home versus hospital IV
treatment
Carswell 1987 Not relevant participants - trial of P. aeruginosa treatment.
Chua 1990 Not a relevant intervention - used differing tonicities of inhaled antibiotics to assess airway responsiveness
Conway 1996 Not relevant participants - did not differentiate between organisms causing exacerbation leading to inclusion
into the trial
Cooper 1985 Not relevant participants - trial of P. aeruginosa treatment.
Dalbøge 2013 An observational study. Not randomised.
Davis 1987 Pharmocokinetic study.
Degg 1996 Not a relevant intervention or relevant participants - study on long-term effects of gentamicin on hearing.
Participants not selected on basis of microbial colonisation
Dodd 1997 Not a relevant intervention or relevant participants - testing differences in lung function relating to tonicity
of nebulised colistin
Dodd 1998 Not a relevant intervention or relevant participants - a compliance study. No suitable control
Garske 2004 An observational study.
Geller 2004 Pharmocokinetic study.
Goldfarb 1986 Pharmocokinetic study.
Grifﬁth 2008 Pharmocokinetic/tolerability study.
Gulliver 2003 Not a relevant intervention or relevant participants - testing whether nebulised IV tobramycin solution
induced cough or bronchoconstriction or both
Heininger 1993 Not relevant participants - trial of P. aeruginosa treatment.
Hjelte 1988 Not relevant participants - investigated affect of home IV antibiotics for P. aeruginosa on quality of life.
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(Continued)
Huang 1979 Not relevant participants - did not differentiate between organisms causing exacerbation leading to inclusion
into trial
Huls 2000 Pharmocokinetic study.
Junge 2001 Not relevant participants - investigating risk of ototoxicity or cochlea damage in once daily versus 3-times
daily IV tobramycin
Kapranov 1995 Not relevant participants - trial of P. aeruginosa treatment.
Keel 2011 Pharmocokinetic study.
Keller 2010 Pharmocokinetic study.
Knight 1979 Not relevant participants - trial of P. aeruginosa treatment.
Labiris 2004 Not a relevant intervention or relevant participants - objective was to determine whether preservative con-
taining inhaled tobramycin causes airway inﬂammation
Loening -Bauke 1979 Not a relevant intervention - used cephalexin as prophylaxis
Macfarlane 2007 An observational study.
Maiz 1998 A case report of one 10-year old boy.
Nathanson 1985 Not relevant participants - trial of P. aeruginosa treatment.
Nolan 1982 Not a relevant intervention - prophylaxis rather than eradication
Pai 2006 Pharmocokinetic study.
Postnikov 2000 Not relevant participants - compared children with CF and aplastic anaemia
Postnikov 2001a Not a relevant intervention or relevant participants - describes risk of quinolone arthropathy in children
Postnikov 2001b Not a relevant intervention or relevant participants - investigated the effect on growth with the addition of
ciproﬂoxacin to the treatment of children with CF
Ramstrom 2000 Not a relevant intervention - compared quality of life scores in patients who received pre-made infusion
devices compared to those who reconstituted drugs themselves
Roberts 1993 Pharmocokinetic study.
Romano 1991 Not relevant participants - trial of P. aeruginosa treatment.
Rosenfeld 2006 Pharmocokinetic study.
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(Continued)
Sahl 1992 Not relevant participants - MRSA not required for entry into study
Serisier 2004 A case report of one 28-year old man.
Shapera 1981 Not relevant participants - did not differentiate between MRSA and MSSA in inclusion criteria. Unclear
how randomisation was achieved
Smith 1997 Pharmocokinetic study.
Solis 2003 Retrospective study.
Stutman 1987 Not relevant participants - pharmacokinetic study of P. aeruginosa treatment.
Vanderhelst 2013 An observational study. Not randomised.
Vitti 1975 Pharmocokinetic study.
Wood 1996 Not a relevant intervention - compared aminoglycoside toxicity in twice and 3-times daily dosing regimens
CF: cystic ﬁbrosis
IV: intravenous
MRSA: meticillin-resistant Staphylococcus aureus
MSSA: meticillin-sensitive Staphylococcus aureus
P. aeruginosa: Pseudomonas aeruginosa
Characteristics of ongoing studies [ordered by study ID]
NCT01349192
Trial name or title Early meticillin-resistant Staphylococcus aureus (MRSA) therapy in cystic ﬁbrosis (CF) (STAR-Too).
Methods Randomized, open-label, multicentre study comparing use of an eradication protocol to an observational
group receiving the current standard of care, i.e. treatment for MRSA only with pulmonary exacerbations
Participants Participants will include people≥4 and≤45 years with CF and new isolation of MRSA from their respiratory
culture on a routine clinic visit. Estimated enrolment is 80
Interventions Eradication protocol: 14-day oral rifampicin plus TMP-SMX or minocycline in people with contraindica-
tions to TMP-SMX
Observational group: current standard of care, i.e. treatment for MRSA only with pulmonary exacerbations
Drug: rifampin (adult dose: 300 mg twice daily for 14 days; paediatric dose: <40 kg: 15 mg/kg daily for 14
days divided every 12 hours).
Drug: TMP-SMX (adult dose: 320/1600 orally twice daily for 14 days; paediatric dose: <40 kg: 8 mg/kg
trimethoprim, >40 mg/kg sulfamethoxazole twice daily for 14 days).
Drug: minocycline (only participants 8 years of age or older, who are not able to tolerate TMP/SMX or whose
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NCT01349192 (Continued)
screening MRSA is resistant to TMP/SMX, should be prescribed minocycline. Adult dose: 100 mg orally
twice daily for 14 days. Paediatric dose: <50 kg: 2 mg/kg orally twice daily for 14 days not to exceed 200 mg
per day).
Drug: mupirocin (1 g 2% nasal ointment generously applied to each nostril using a cotton swab twice daily
for 14 days).
Drug: chlorhexidine gluconate oral rinse (0.12% chlorhexidine gluconate oral rinse twice daily for 14 days).
Drug: 2% chlorhexidine solution wipes (whole body wash solution wipes once daily for the ﬁrst 5 days).
Behavioral: environmental decontamination (wipe down high-touch surfaces and medical equipment with
surface disinfecting wipes daily for the ﬁrst 21 days. Wash all linens and towels in hot water once weekly for
3 weeks)
Outcomes Primary outcome measure
1. Proportion of participants in each arm with MRSA-negative respiratory cultures at day 28.
Secondary outcome measures
1. Proportion of participants treatedwith oral, inhaled, and IV antibiotics over the 6-month study and number
of days of use
2. Proportion of participants with a protocol-deﬁned pulmonary exacerbation between baseline and day 28
who are treated with antibiotics active against MRSA
Starting date April 2011.
Contact information Marianne S Muhlebach, MD, University of North Carolina, Chapel Hill
Notes Study closed for enrolment but some participants are still being actively followed up. Data analyses expected
to begin in 2015
NCT01594827
Trial name or title Persistent meticillin resistant Staphylococcus aureus eradication protocol (PMEP)
Methods Randomised, placebo-controlled parallel trial.
Duration 28 days with additional 3-month follow-up.
Participants will be assigned in a 1:1 ratio to either treatment or control group
Participants 40 participants with persistent respiratory tract MRSA infection will be enrolled in this trial
Inclusion criteria:
1. male or female ≥ 12 years of age;
2. conﬁrmed diagnosis of CF based on the following criteria: positive sweat chloride > 60 mEq/liter (by
pilocarpine iontophoresis) and/or a genotype with 2 identiﬁable mutations consistent with CF or abnormal
NPD, and 1 or more clinical features consistent with the CF phenotype;
3. written informed consent (and assent when applicable) obtained from participant or participants’s legal
representative and ability for participant to comply with the requirements of the study;
4. 2 positive MRSA respiratory cultures in the last 2 years at least 6 months apart, plus a positive MRSA
respiratory culture at screening visit and run-in (day 14) visit;
5. at least 50% of respiratory cultures from the time of the ﬁrst MRSA culture (in the last 2 years) have
been positive for MRSA;
6. FEV1 > 30% of predicted normal for age, gender, and height at screening;
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7. females of childbearing potential must agree to practice 1 highly effective method of birth control,
including abstinence. Note: highly effective methods of birth control are those, alone or in combination,
that result in a failure rate less than 1% per year when used consistently and correctly. Female participants
who utilize hormonal contraceptives as a birth control method must have used the same method for at least
3 months before study dosing. If the participant is using a hormonal form of contraception, she will be
required to also use barrier contraceptives as rifampin can affect the reliability of hormone therapy. Barrier
contraceptives such as male condom or diaphragm are acceptable if used in combination with spermicides.
Interventions Treatment group: 28-day course of inhaled vancomycin for inhalation (250 mg twice-a-day) plus oral ri-
fampicin and oral TMP/SMX
Control group: taste-matched inhaled placebo (sterile water) plus oral rifampicin and oral TMP/SMX
In addition, both groups will receive oral rifampin, a second oral antibiotic (TMP-SMX or doxycycline,
protocol determined), mupirocin intranasal cream and chlorhexidine body washes
Outcomes Primary objectives
1. To determine the efﬁcacy of an aggressive treatment protocol in eradicating persistent MRSA infection in
individuals with CF
2. To determine the safety of an aggressive treatment protocol in eradicating persistent MRSA infection in
individuals with CF
Secondary objectives
1. To determine the efﬁcacy of an aggressive treatment protocol in improving FEV1, time to next exacerbation,
and quality of life in individuals with CF and persistent MRSA infection
2. To determine if there is beneﬁt to adding nebulized vancomycin to an aggressive oral antibiotic treatment
protocol in eradicating persistent MRSA infection in individuals with CF
Starting date Oct 2012.
Contact information Michael Boyle, Associate Professor of Medicine, Johns Hopkins University
Notes Currently actively recruiting. Estimated completion date: March 2015
NCT01746095
Trial name or title Efﬁcacy and safety study of AeroVanc for the treatment of persistent MRSA lung infection in cystic ﬁbrosis
patients
Methods Randomised, double-blind, placebo-controlled trial.
Duration 28 days with additional 56 days follow up.
There will be two treatment cohorts in this study, each comprised of 40 randomized (1:1 active to placebo)
participants. In Cohort 1, participants will be randomized to receive the 32 mg dose of AeroVanc twice daily
or placebo twice daily. Prior to starting enrolment in Cohort 2, a safety evaluation will be carried out by the
DMC based on treatment data from the ﬁrst 20 participants in Cohort 1. Subject to the Sponsor’s written
communication of the DMC’s opinion of acceptable safety, the dose for the active arm in Cohort 2 will be
escalated to 64 mg twice daily. Optionally, the active arm for Cohort 2 may also be kept the same (32 mg
twice daily), or reduced to 16 mg twice daily, depending on the outcome of the DMC’s safety evaluation
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Participants 87 participants with persistent respiratory tract MRSA infection have been enrolled onto this trial
Inclusion criteria:
1. adults ≥18 years old (and the legally authorized representatives of children ≥12 but <18 years old).
Children ≥12 but <18 years old: able to communicate with site personnel and to understand and
voluntarily sign the assent form;
2. able and willing to comply with the protocol, including availability for all scheduled study visits;
3. have a conﬁrmed diagnosis of CF, determined by having clinical features consistent with the CF
phenotype, plus 1 of the following: a) positive sweat chloride test (value ≥60 mEq/L), or b) genotype with
two mutations consistent with CF (i.e., a mutation in each of the CFTR genes);
4. be ≥12 years old at time of informed consent form or assent form signing;
5. have sputum culture positive for MRSA at screening, with at least 10,000 CFUs/mL of MRSA;
6. in addition to the screening sample, have at least 2 historical respiratory tract cultures (i.e., sputum
and/or throat swab) positive for MRSA prior to screening and evidence that the MRSA lung infection has
persisted for at least 6 months prior to screening;
7. have FEV1 % predicted ≥30% and ≤100% normalized for age, gender, and height at screening;
8. evidence, deﬁned as 1 or both of the following, that the persistent MRSA lung infection is suspected to
be causing health consequences; have had at least 1 episode of acute pulmonary infection treated with non-
maintenance antibiotics within 12 months from screening (initiation of treatment with intermittent inhaled
anti-Pseudomonas therapy will not qualify as treatment with non-maintenance antibiotics); requires anti-
MRSA treatment as part of a maintenance regimen to prevent pulmonary exacerbations or other respiratory
symptoms;
9. be able to perform all the techniques necessary to use the AeroVanc inhaler and measure lung function;
10. be able to produce expectorated sputum samples or be able and willing to undergo standardized
sputum induction;
11. agree not to smoke from screening through the end of the study;
12. females of child-bearing potential are eligible to participate in this study only if they are NOT
pregnant or lactating, and if they are using a highly effective method of birth control;
13. participants with P. aeruginosa co-infection must either be stable on a regular suppression regimen of
inhaled antibiotics or must be, in the opinion of the investigator, stable despite the lack of such treatment.
Participants on a Cayston-based therapy must have received at least 2 cycles of Cayston prior to baseline
(can be 2 consecutive months or 2 cycles over 4 months).
Interventions Treatment group: A 28-day course of inhaled vancomycin (AeroVanc) starting at 32 mg twice per day, and
either (a) increased (64 mg twice per day), (b) kept the same (32 mg twice per day), or (c) reduced (16 mg
twice per day) pending initial safety evaluation
Control group: A 28-day course of placebo inhalation powder.
Outcomes Primary outcome measure
1.Change frombaseline atDay 29of the dosingperiod (start of AeroVanc/Placebo administration is considered
Day 1 of the dosing period) in the number of MRSA CFUs in sputum culture
Secondary outcome measures
1. Change from baseline in each pulmonary function test.
2. Change from baseline in Cystic Fibrosis Respiratory Symptom Diary scores
3. Change from baseline in MRSA sputum density.
4. Time from start of dosing to ﬁrst administration of other antimicrobial medications (oral, intravenous and/
or inhaled) due to respiratory symptoms
5. Time from start of dosing to exacerbation of signs/symptoms (Fuchs criteria)
6. Change from baseline in high sensitivity C-reactive protein and blood neutrophils
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Starting date March 2013.
Contact information Elliott Dasenbrook, MD. Case Western Reserve University School of Medicine and Rainbow Babies and
Children’s Hospital
Notes Study completed November 2014. No results posted as of 14th December 2014
CF: cystic ﬁbrosis
CFTR: cystic ﬁbrosis transmembrane conductance regulator
CFU: colony forming unit
DMC: Data Monitoring Committee
FEV1: forced expiratory volume at one second
MRSA: meticillin-resistant Staphylococcus aureus
P. aeruginosa : Pseudomonas aeruginosa
NPD: nasal potential difference
TMP-SMX: trimethoprim/sulfamethoxazole
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D A T A A N D A N A L Y S E S
This review has no analyses.
A P P E N D I C E S
Appendix 1. Search strategy for MEDLINE (1950 - December 2014) and Embase (1980 - December
2014)
1 Embase, MEDLINE (methicillin AND resistant AND
staphylococcus AND aureus OR
MRSA OR methicillin AND
resistant AND staphylococcus
AND aureus OR methicillin
AND staphylococcus).ti,ab
40457 Apply Limits
2 Embase, MEDLINE (cystic AND ﬁbrosis).ti,ab 68893 Apply Limits
3 Embase, MEDLINE (eradication OR eradica*).ti,ab 86661 Apply Limits
4 Embase, MEDLINE 1 AND 2 AND 3 38 Apply Limits
WH A T ’ S N E W
Last assessed as up-to-date: 18 February 2015.
Date Event Description
18 February 2015 New citation required but conclusions have not
changed
Given that no new data have been added to this review,
our conclusions remain the same
18 February 2015 New search has been performed A search of the Cystic Fibrosis and Genetic Disorders
Group’sCystic FibrosisTrialsRegister identiﬁedno new
studies to be included in this review
A search of PUBMED, Embase and MEDLINE iden-
tiﬁed a further three studies, none of which were eligi-
ble for inclusion in the analysis (Dalbøge 2013; Serisier
2004; Vanderhelst 2013).
A search of the ongoing
trials registers (www.clinicaltrials.gov; www.isrctn.org)
identiﬁed one further ongoing study, which has been
listed in the review (NCT01746095).
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C O N T R I B U T I O N S O F A U T H O R S
Roles and responsibilities
TASK WHO WILL UNDERTAKE THE TASK?
Protocol stage: draft the protocol David Lo
Review stage: select which trials to include (2 + 1 arbiter) David Lo, Matthew Hurley, Marianne Muhlebach, Alan Smyth
Review stage: extract data from trials (2 people) David Lo, Matthew Hurley
Review stage: enter data into RevMan David Lo
Review stage: carry out the analysis David Lo, Matthew Hurley
Review stage: interpret the analysis David Lo, Matthew Hurley, Marianne Muhlebach, Alan Smyth
Review stage: draft the ﬁnal review David Lo, Matthew Hurley
Update stage: update the review David Lo
D E C L A R A T I O N S O F I N T E R E S T
David Lo and Matthew Hurley: none known.
Marianne Muhlebach is one of the principle investigators for a randomised controlled study evaluating early treatment of MRSA; this
study is currently in progress (NCT01349192).
Alan Smyth is the Co-ordinating Editor of the Cochrane Cystic Fibrosis and Genetic Disorders Group and declares relevant activities
of: membership of a REMPEX steering committee; consultancies for Novartis, Biocontrol and Rempex Pharma (both make aerosolised
antibiotics which are active against some strains of Staphylococcus aureus); and also a lecture paid for by Chiesi Pharma.
S O U R C E S O F S U P P O R T
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• No sources of support supplied
External sources
• National Institute for Health Research, UK.
This systematic review was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to the
Cochrane Cystic Fibrosis and Genetic Disorders Group.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
In the 2015 update we have changed the spelling of ’methicillin’ to ’meticillin’ in line with the change in the international non-
proprietary name (although we are aware that in some parts of the world the drug is still known as methicillin).
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Methicillin-Resistant Staphylococcus aureus; Cystic Fibrosis [∗microbiology]; Staphylococcal Infections [∗prevention & control]
MeSH check words
Humans
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